Rezolute Inc said on Monday the U.S. Food and Drug Administration has removed the partial clinical hold on its late-stage study testing its treatment for low blood sugar,...
-Rezolute Inc said on Monday the U.S. Food and Drug Administration has removed the partial clinical hold on its late-stage study testing its treatment for low blood sugar, sending its share up 11% at $4.83 in premarket trading.
The treatment, ersodetug, is currently being tested on participants with congenital hyperinsulinism, a genetic disorder that causes low blood sugar. Rezolute anticipates potential U.S. enrollment for the study to begin in early 2025, and expects to announce results in the second half of 2025. The study is enrolling up to 56 participants in more than a dozen countries, with eligibility ranging from three months to 45 years of age, the company said.Reuters Ltd.
Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
Genomic Medicine Blood Genetic Disorder Persistent Hyperinsulinemic Hypoglycemia Of Infanc Congenital Hyperinsulinism Congenital Hyperinsulinemic Hypoglycemia Genetics
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Snowflake lifts annual guidance after Q2 results top Wall Street estimatesSnowflake lifts annual guidance after Q2 results top Wall Street estimates
Read more »
Boerne's 'little brother' lifts his team in big moment in LLWSBoerne's 'little brother' lifts his team in big moment in Little League World Series
Read more »
Tennessee Titans vs. New Orleans Saints - Final ScoreWillis TD lifts Titans over Saints
Read more »
SentinelOne lifts annual revenue guidance after Q2 results top analyst estimatesSentinelOne lifts annual revenue guidance after Q2 results top analyst estimates
Read more »
Abercrombie & Fitch lifts annual sales forecast betting on steady demandAbercrombie & Fitch lifts annual sales forecast betting on steady demand
Read more »
Gitlab lifts guidance as Q2 results top estimates amid margin expansionGitlab lifts guidance as Q2 results top estimates amid margin expansion
Read more »